Gentulizumab
Gentulizumab (Gensci-059) is a humanized IgG4 antibody that targets CD47. Gentulizumab displays strong binding to CD47 in both human and monkey, and effectively inhibits the CD47-SIRPα interaction. Gentulizumab exhibits a potent antitumor activity. The isotype control for Gentulizumab can refer to Human IgG4 (S228P) kappa, Isotype Control.
Product Specifications
Product Name Alternative
Gensci-059
UNSPSC
12352203
Target
CD47
Related Pathways
Immunology/Inflammation
Applications
Cancer-programmed cell death
Field of Research
Cancer
Purity
97.02
Smiles
[Gentulizumab]
Molecular Weight
(145.97 kDa)
References & Citations
[1]Wang T, et al. Gentulizumab, a novel anti-CD47 antibody with potent antitumor activity and demonstrates a favorable safety profile. J Transl Med. 2024 Mar 1;22 (1) :220.
Shipping Conditions
Dry Ice
Storage Conditions
-80°C
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 1
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC470500-100 1x 100 µL
Progesterone Receptor (PR500), CF647 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC400833-500 1x 500 µL
Calponin-1 (CALP + CNN1/832), CF640R conjugate, 0.1mg/mL
Sign In for Pricing
View Details